Natural compounds as inhibitors of SARS-CoV-2 endocytosis: A promising approach against COVID-19

Main Article Content

Aysha Karim Kiani
Kristjana Dhuli
Kyrylo Anpilogov
Simone Bressan
Matteo Bertelli


SARS-CoV-2, COVID-19, natural antiviral compounds, endocytosis


Background and aim: The recent COVID-19 pandemic caused by SARS-CoV-2 affected more than six million people and caused thousands of deaths. The lack of effective drugs or vaccines against SARS-CoV-2 further worsened the situation. This review is focused on the identification of molecules that may inhibit viral entry into host cells by endocytosis. Methods: We performed the literature search for these natural compounds in the articles indexed in PubMed. Results: Natural products against viral infections have been gaining importance in recent years. Specific natural compounds like phytosterols, polyphenols, flavonoids, citrus, galangal, curcuma and hydroxytyrosol are being analyzed to understand whether they could inhibit SARS-CoV-2. Conclusions: We reviewed natural compounds with potential antiviral activity against SARS-CoV-2 that could be used as a treatment for COVID-19.


Download data is not yet available.


Metrics Loading ...
Abstract 55 |


[1] Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69: 635-64.
[2] Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16: 69.
[3] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.
[4] Chen H, Du Q. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection. Preprint 2020. doi:10.20944/preprints202001.0358.v3
[5] Yan R, Zhang YYL, Xia L, Guo YY, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-8.
[6] Haider Z, Subhani MM, Farooq MA, et al. In silico discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 using pharmacophore and molecular docking based virtual screening from ZINC database. Preprint 2020. doi:10.20944/preprints202002.0431.v1
[7] Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA. Preprint 2020. doi:10.20944/preprints202003.0333.v1
[8] Yang N, Shen H-M. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci 2020; 16: 1724.
[9] Baglivo M, Baronio M, Natalini G, et al. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Acta Biomed 2020; 91: 161-4.
[10] de Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res 2005; 64: 165-230.
[11] Millet JK, Whittaker GR. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology 2018; 517: 3-8.
[12] Sun P, Lu X, Xu C, Wang Y, Sun W, Xi J. CD‐sACE2 inclusion compounds: an effective treatment for coronavirus disease 2019 (COVID‐19). J Med Virol 2020. doi:10.1002/jmv.25804
[13] Jia HP, Look DC, Tan P, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009; 297: L84-96.
[14] Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112-6.
[15] Tan S, Ladewig K, Fu Q, Blencowe A, Qiao GG. Cyclodextrin‐based supramolecular assemblies and hydrogels: recent advances and future perspectives. Macromol Rapid Commun 2014; 35: 1166-84.
[16] Le Roy C, Wrana JL. Clathrin-and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005; 6: 112-26.
[17] Tarahovsky YS, Muzafarov EN, Kim YA. Rafts making and rafts braking: how plant flavonoids may control membrane heterogeneity. Mol Cell Biochem 2008; 314: 65.
[18] Li G-M, Li Y-G, Yamate M, Li S-M, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect 2007; 9: 96-102.
[19] Bender FC, Whitbeck JC, de Leon MP, Lou H, Eisenberg RJ, Cohen GH. Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol 2003; 77: 9542-52.
[20] Glende J, Schwegmann-Wessels C, Al-Falah M, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology 2008; 381: 215-21.
[21] Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta Biomembr 2007; 1768: 1311-24.
[22] Rezanka T, Siristova L, Sigler K. Sterols and triterpenoids with antiviral activity. Antiinfect Agents Med Chem 2009; 8: 193-210.
[23] Zakaryan H, Arabyan E, Oo A, Zandi K. Flavonoids: promising natural compounds against viral infections. Arch Virol 2017; 162: 2539-51.
[24] Ferrer J-L, Austin M, Stewart Jr C, Noel J. Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol Biochem 2008; 46: 356-70.
[25] Lalani S, Poh CL. Flavonoids as antiviral agents for Enterovirus A71 (EV-A71). Viruses 2020; 12: 184.
[26] Jeong HJ, Ryu YB, Park S-J, et al. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem 2009; 17: 6816-23.
[27] Schwarz S, Sauter D, Wang K, et al. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med 2014; 80: 177-82.
[28] Yan H, Ma L, Wang H, et al. Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. J Nat Med 2019; 73: 487-96.
[29] Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P. The green tea molecule EGCG inhibits Zika virus entry. Virology 2016; 496: 215-8.
[30] Szabo G, Dolganiuc A, Dai Q, Pruett SB. TLR4, ethanol, and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects. J Immunol 2007; 178: 1243-9.
[31] Wang H, Cui Y, Fu Q, et al. A phospholipid complex to improve the oral bioavailability of flavonoids. Drug Dev Ind Pharm 2015; 41: 1693-1703.
[32] Carrouel F, Conte MP, Fisher J, et al. COVID-19: a recommendation to examine the effect of mouthrinses with β-cyclodextrin combined with Citrox in preventing infection and progression. J Clin Med 2020; 9: 1126.
[33] Yu M-S, Lee J, Lee JM, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett 2012; 22: 4049-54.
[34] Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-74.
[35] Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. Saudi Pharm J 2017; 25: 149-64.
[36] Tarahovsky YS, Kim YA, Yagolnik EA, Muzafarov EN. Flavonoid–membrane interactions: involvement of flavonoid–metal complexes in raft signaling. Biochim Biophys Acta Biomembr 2014; 1838: 1235-46.
[37] Williams RJ, Spencer JP, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 2004; 36: 838-49.
[38] Zheng Y, Lim EJ, Wang L, Smart EJ, Toborek M, Hennig B. Role of caveolin-1 in EGCG-mediated protection against linoleic-acid-induced endothelial cell activation. J Nutr Biochem 2009; 20: 202-9.
[39] Yamada K, Ogawa H, Hara A, et al. Mechanism of the antiviral effect of hydroxytyrosol on influenza virus appears to involve morphological change of the virus. Antiviral Res 2009; 83: 35-44.